Merseburger Discusses Future Research of PRESIDE Trial Enzalutamide Combo

Axel Merseburger, MD, PhD, spoke about implementing the treatment combination of enzalutamide plus docetaxel/prednisone for progressive castration-resistant prostate cancer from the PRESIDE trial into the real-world.

In an interview with CancerNetwork® during the 2022 Genitourinary Cancers Symposium, Axel Merseburger, MD, PhD, chairman of the Clinic of Urology at University Hospital Schleswig-Holstein in Lübeck, Germany, discussed next steps following results of the PRESIDE trial (NCT02288247) looking at benefit of continued enzalutamide (Xtandi) therapy for men with metastatic castration-resistant prostate cancer (mCRPC).1

Transcript:

Our next steps are digging into the basic research part of the PRESIDE trial. We have various biomarkers like circulating tumor cells at specific time points, and this will be investigated. I’m looking forward to [if they are] going to find a correlation. Biomarkers within a trial like PRESIDE make sense, because we want to identify the men that are of high risk and would benefit the most with continuation with enzalutamide treatment. As we have seen, the PFS benefit wasn’t that big; it was about a couple of months vs years like in PEACE-1 [NCT01957436] in those with mHSPC [metastatic hormone-sensitive prostate cancer].2 We are in a different scenario, we are talking about mCRPC and the continuation with enzalutamide might make sense, hopefully with biomarkers into which we will report at future conferences. Hopefully, this will shed more light on the question of which men benefit most from maintaining and treating upon progression with enzalutamide in mCRPC.

References

1. Merseburger A, Attard G, Boysen G, et al. A randomized, double-blind, placebo (PBO)-controlled, phase 3b study of the efficacy and safety of continuing enzalutamide (ENZA) in chemotherapy-naïve, metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with docetaxel (DOC) plus prednisolone (PDN) who have progressed on ENZA: PRESIDE. J Clin Oncol. 2022;40(suppl 6):15. doi: 10.1200/JCO.2022.40.6_suppl.015

2. Fizazi K, Carles Galceran J, Foulon S, et al. A phase III trial with a 2x2 factorial design in men with de novo metastatic castration-sensitive prostate cancer: Overall survival with abiraterone acetate plus prednisone in PEACE-1. Annals of Oncol. 2021;32(suppl_5):S1283-S1346. doi: 10.1016/annonc/annonc741